16 results about "Hippuric acid" patented technology

There is provided a method for diagnosing a subject with early onset muscle atrophy, said method comprising: obtaining a biosample from the subject; and assaying the biosample for one or more biomarkers, said one more biomarkers are taurine, proline, citrulline, trigonelline, thymidine, ornithine, glutamate, L-pyroglutamic acid, creatinine, adenine, nicotinamide, 2-methylhippuric acid, maltol, L-arginine, hypotaurine, L-glutamine, homogentisic acid, methylhistidine, oxoglutaric acid, xanthine, L-carnitine, succinate, or a combination thereof; and identifying the subject with early onset muscle atrophy on the basis of a deviation in the one or more of said one more biomarkers.

The invention discloses an endogenous small molecule metabolite for treating obesity and related metabolic diseases thereof, and belongs to the field of biological medicine. Specifically, the invention relates to application of hippuric acid in preparation of anti-obesity drugs. The invention discloses a technical scheme for treating obesity and related metabolic disorders by hippuric acid, and overcomes the defects of single curative effect, larger side effect or unclear action mechanism and the like in the prior art through the advantages of targeted improvement of liver fatty degeneration, improvement of insulin sensitivity, higher potential safety, provision of a new treatment strategy and the like. The method has remarkable technical progress and clinical application value.

The invention relates to the technical field of marine microorganisms, in particular to application of combined lactobacillus salivarius in preparation of products for improving metabolism of alcohol and uric acid, the combined lactobacillus salivarius NHNK-603 is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 2024416. Experiments show; the NHNK-603 has the effects of inhibiting the growth of klebsiella pneumoniae, inhibiting the production of alcohol, agglutinating the klebsiella pneumoniae, inhibiting the virulence gene of the klebsiella pneumoniae, promoting alcohol metabolism, reducing alcohol damage, tolerating alcohol, degrading uric acid, inhibiting the activity of xanthine oxidase, promoting uric acid excretion, promoting the proliferation of Alistipes indinctus and synthesizing hippuric acid; the thallus biofilm increases the function of colonization on mucoprotein and intestinal epithelial cells, and can be applied to preparation of products for improving metabolism of alcohol and uric acid.

The present invention provides a pharmaceutical composition comprising a radiolabeled complex comprising a radionuclide and a targeting moiety linked to a chelating moiety, and a stabilizer against radiolytic degradation of a radiolabeled complex comprising para-aminohippuric acid or a pharmaceutically acceptable salt or carboxylic derivative thereof. The pharmaceutical composition of the present invention is characterized by high stability of its radiolabeled complex against radiolytic degradation. The present invention also provides a method for preparing such a pharmaceutical composition, and use of para-aminohippuric acid or a pharmaceutically acceptable salt or carboxylic derivative thereof for the stabilization of the radiolabeled complex of such a pharmaceutical composition.

The application provides a molecular imprinting electrochemical sensor for hippuric acid detection, a preparation method and a segmented response technology, and belongs to the technical field of electrochemical sensors.The molecular imprinting electrochemical sensor for detecting hippuric acid is prepared by an electrochemical polymerization method based on a functional monomer aniline and o-phenylenediamine and taking hippuric acid as a template molecule.The sensor combines the advantages of molecular imprinting technology and electrochemical technology, has excellent sensitivity, fast response time and specific recognition ability, has good signal response for hippuric acid detection under different concentrations, generates a good electric signal in a 0-100nM hippuric acid solution, and forms a better linear relationship between the electric signal and the concentration in a hippuric acid solution with a concentration of more than 100nM, so that the signal response and detection range of the molecular imprinting electrochemical sensor under high concentration are widened, and the molecular imprinting electrochemical sensor is suitable for hippuric acid detection under a wide range.

Provided are a salt and / or a crystal form of a compound degrading BTK and preparation and application thereof. The pharmaceutically acceptable salt and crystal form of the compound as shown in formula (I), wherein the pharmaceutically acceptable salt is selected from a maleate salt, a fumarate salt, a hydrogen halide salt (preferably a hydrobromide salt and a hydrochloride salt), a sulfate salt, a phosphate salt, an L-tartrate salt, a citrate salt, an L-malate salt, a hippurate salt, a D-glucuronate salt, a glycolate salt, a mucate salt, a succinate salt, a lactate salt, an orotate salt, a pamoate salt, a glycine salt, an alanine salt, an arginine salt, a cinnamate salt, a benzoate salt, a benzene sulfonate salt, a p-toluene sulfonate salt, an acetate salt, a propionate salt, a valerate salt, a triphenylacetic acid salt, an L-proline salt, a ferulic acid salt, a 2-hydroxyethanesulfonate salt, a mandelate salt, a nitrate salt, a methanesulfonate salt, a malonate salt, a gentisate salt, a salicylate salt, an oxalate salt or a glutarate salt:

The invention discloses application of hippuric acid in activation of brown adipose tissue heat production and prevention and treatment of obesity, and the application is realized by activating brown adipose tissue heat production, specifically, expression of uncoupling protein 1 in brown adipose tissue is up-regulated, heat production capacity under cold stimulation conditions is enhanced, weight gain and abnormal glucose and lipid metabolism are improved, and the purpose of preventing and treating obesity is achieved. The hippuric acid is preferably derived from walnut oil or metabolites thereof, and has a good application prospect.

Provided are a free base or pharmaceutically acceptable salt of a pyrazoloquinazoline compound of formula (I), which can be used as a PLK1 inhibitor, optionally in a crystalline form, and a solvate or hydrate thereof, wherein the pharmaceutically acceptable salt comprises a hydrochloride, sulfate, phosphate, maleate, fumarate, L-tartrate, citrate, L-aspartate, hippurate, L-glutamate, L-malate, adipate, glutarate, p-toluenesulfonate, and methanesulfonate of the pyrazoloquinazoline compound of formula (I), and also provided is a pharmaceutical composition comprising same, and a use thereof in the treatment of diseases and conditions caused by dysregulated activity of PLK1 and / or diseases and conditions related to PLK1, such as cancer.

Disclosed herein are methods for promoting healthy neural development in an unborn baby, which include administering to a maternal subject gestating the unborn baby a composition or a bacterial composition. Compositions can include trimethylamine N-oxide (TMAO), 5-aminovalerate (5-AV), imidazole propionate (IP), hippurate (HIP), or a combination thereof, and the bacterial compositions can include bacteria of the order Clostridiales. Also disclosed are methods for conditioning a female subject for bringing about offspring with healthy neural development. Additionally disclosed are methods for reducing adverse effects of antibiotic treatment on an unborn baby in a pregnant subject. Also disclosed are methods for selecting a female subject for conditioning to foster healthy neural development in offspring.

The application discloses application of hippuric acid in preparation of a medicine for preventing and / or treating depression, and belongs to the technical field of biological medicine. The hippuric acid or pharmaceutically acceptable salt thereof has significant and multi-target antidepressant pharmacological activity through chronic mild stress depression animal model experiment. Specifically, in terms of improving core depressive symptoms, the sugar water preference experiment result shows that the hippuric acid can effectively reverse CUMS-induced hedonic deficiency of mice, and significantly improves the sucrose preference rate, and the forced swimming experiment proves that the hippuric acid can significantly shorten the immobility time of mice and relieve behavioral despair; in terms of improving anxiety-like behavior, the mine field experiment data show that after the hippuric acid intervention, the number of times of entering the central area, the residence time and the total activity distance of the depressive model mice are all significantly increased, which indicates that the hippuric acid can effectively improve the spontaneous activity reduction caused by chronic stress.

The application provides an anisaldehyde hippuric acid molecular top and a preparation method and application thereof, and belongs to the technical field of detection of gibberellic acid liquid preparation. The anisaldehyde hippuric acid molecular top has a unique configuration of a rigid aromatic ring rotor and an amide bond flexible support shaft, can convert micro-viscosity changes into visual light signal output, and releases light signal intensity that regularly increases with the increase of micro-viscosity, so that the dilution degree of the gibberellic acid liquid preparation can be observed in real time and accurately controlled. The sensitive coefficient of the MBABG to viscosity is high (x=0.65), the conjugated system formed by the amide bond and the aromatic ring in the molecular structure of the MBABG gives the MBABG excellent chemical stability, the MBABG can resist the complex environment of multiple components such as thickening agents, surfactants and pH regulators in the gibberellic acid liquid preparation, and can exist stably for a long time.

The invention discloses an animal model construction method for fetal osteoporosis, a prevention and treatment target and application of the prevention and treatment target. The fetal osteoporosis animal model is a filial generation rat which is obtained after a pregnant female Wistar rat is subjected to intragastric administration of Acimoline (300 mg / kg. D) in the pregnancy period. Weaning is conducted four weeks after birth, male and female are separated from cages and fed to 12 weeks, the peak bone mass of female offspring is remarkably reduced, and therefore the animal model with exposed Acimoline during pregnancy is established. On the basis of a pregnancy-stage Acimoline exposed rat model, 20 mg / kg hippuric acid is intragastric injected in the pregnancy stage, and peak bone mass reduction of female offspring can be effectively corrected. The animal model established by the invention is novel, reliable, simple and convenient, and application of hippuric acid in screening and preparing medicines for preventing and treating fetal osteoporosis is determined.

The invention discloses a metabolic marker combination, a detection kit and application thereof, an establishment method of an arteriosclerosis level prediction model and an arteriosclerosis level evaluation method. The metabolic marker combination comprises 2-hydroxybutyric acid, hydrocinnamic acid, 2-phenylpropionic acid, 5 [beta]-androstane-3 [beta]-ol-17 [beta]-carboxylic acid methyl ester, C18: 1 ceramide, vanillic mandelic acid, menadione, piperine, hippuric acid, carnitine, propionyl glycine, myristic acid, urocanic acid, alpha-linolenic acid, methionine and 5-hydroxymethyl-2-furancarboxylic acid. The arteriosclerosis level evaluation can be efficiently and accurately carried out.

The present disclosure relates to various crystalline salts of (R)-2-(4-fluorophenyl)-2-(methylamino) cyclohex-1-one that are useful in the treatment of psychiatric disorders, including the treatment of mood disorders. These salts include their hydrochloride, sulfate, p-toluenesulfonate, mesylate, maleate, phosphate, tartrate, fumarate, citrate, glycolate, malate, and hippurate.

Methods of diagnosing Crohn's disease and ulcerative colitis in subjects is provided based on the determination of metabolites in urine samples, such as serine, hypoxanthine, kynurenine, threonine, indoxylsulfate, phenylacetylglutamine, 5-hydroxy-6-indolyl-O-sulfate, 5-(δ-carboxybutyl) homocysteine, sialic acid, guanidinosuccinic acid (GSA), glutamyl(iso) leucine, trigonelline, cresol sulfate, an anion having m / z: RMT: polarity of 345.1553:0.770: n, aminohippurate: GSA ratiometric biomarker, unknown anion (160.0615:0.830: n): tyrosine ratiometric biomarker and [GSA×Tyr]: [AHA×(an anion having m / z: RMT: polarity of 160.0615:0.830: n)] ratiometric biomarker.